US FDA panel backs Novartis lower dose COPD drug, but rejects higher dose
This article was originally published in Scrip
Executive Summary
A panel of advisers to the US FDA backed approval of the 75mcg dose of Novartis' experimental chronic obstructive pulmonary disease (COPD) drug indacaterol, but rejected the 150mcg dose, which may not bode well for the firm's investigational combination drug containing the higher dose.